Sarepta Therapeutics Inc (SRPT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Douglas S. Ingram
Employees:
840
215 FIRST STREET, SUITE 415, CAMBRIDGE, MA 02142
617-274-4000

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.

Data derived from most recent annual or quarterly report
Market Cap 9.277 Billion Shares Outstanding87.501 Million Avg 30-day Volume 1.005 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.6
Price to Revenue0.0 Debt to Equity1.2824 EBITDA0
Price to Book Value7.9772 Operating Margin0.0 Enterprise Value5.921 Billion
Current Ratio5.563 EPS Growth0 Quick Ratio4.817
1 Yr BETA 1.0203 52-week High/Low 107.03 / 61.28 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score1.1629 Free Cash Flow to Firm -53.586 Million
View SEC Filings from SRPT instead.

View recent insider trading info

Sarepta Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SRPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SRPT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-06 by BOOR KATHRYN JEAN
  • 4: filed on 2022-06-06 by CHAMBERS MICHAEL ANDREW
  • 3: filed on 2022-06-06 by CHAMBERS MICHAEL ANDREW
  • 3: filed on 2022-06-06 by BOOR KATHRYN JEAN
  • 4: filed on 2022-06-03 by BROWN RYAN EDWARD
  • 4: filed on 2022-03-01 by RODINO-KLAPAC LOUISE
  • 4: filed on 2022-03-01 by ESTEPAN IAN MICHAEL
  • 4: filed on 2022-03-01 by BROWN RYAN EDWARD
  • 4: filed on 2021-12-16 by BEHRENS M KATHLEEN
  • 4: filed on 2021-12-14 by GRAY MARY ANN

    • Events (8k)

  • 8-K: filed on 2022-06-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-01-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-10-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-27:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-03:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-05-18:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BOOR KATHRYN JEAN

    • Director
    		 0 2022-06-02 2

    CHAMBERS MICHAEL ANDREW

    • Director
    		 75,194 2022-06-02 2

    BROWN RYAN EDWARD SVP, GENERAL COUNSEL

    • Officer
    		 25,841 2022-06-01 3

    BEHRENS M KATHLEEN

    • Director
    		 153,547 2022-03-07 2

    GRAY MARY ANN

    • Director
    		 17,433 2022-03-07 2

    WIGZELL HANS LENNART RUDOLF

    • Director
    		 24,548 2022-03-07 1

    BARRY RICHARD

    • Director
    		 3,133,396 2022-03-07 1

    NICAISE CLAUDE

    • Director
    		 19,882 2022-03-07 1

    MAYO STEPHEN

    • Director
    		 12,322 2022-03-07 3

    CIAMBRONE WILLIAM EVP

    • Officer
    		 70,099 2022-03-04 1

    RODINO-KLAPAC LOUISE HEAD OF R&D, CSO

    • Officer
    		 120,111 2022-03-04 4

    ESTEPAN IAN MICHAEL CHIEF FINANCIAL OFFICER

    • Officer
    		 80,671 2022-03-04 3

    INGRAM DOUGLAS S PRESIDENT & CEO

    • Officer
    • Director
    		 365,082 2021-11-17 1

    MARTIN JOHN C

    • Director
    		 13,431 2021-03-03 0

    O'NEILL GILMORE NEIL EVP, R&D & CMO

    • Officer
    		 89,070 2021-03-03 0

    BRATICA JOSEPH PRINCIPAL FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-12-11 0

    HOWTON DAVID T EVP, GENERAL COUNSEL

    • Officer
    		 31,871 2020-06-22 0

    MAHATME SANDESH EVP, CFO & CBO

    • Officer
    		 32,272 2020-05-11 0

    BONNEY MICHAEL W

    • Director
    		 9,126 2020-02-28 0

    CUMBO ALEXANDER EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 12,008 2020-02-28 0

    O'NEILL GILMORE NEIL EVP, R&D & CMO

    O'NEILL GILMORE NEIL EVP, R&D & CMO

    • Officer
    		 0 2019-03-04 0

    RUFF SHAMIM SVP, CHIEF REGULATORY AFFAIRS

    • Officer
    		 31,936 2018-05-22 0

    BASI GURIQBAL S. SVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2018-03-05 0

    KAYE EDWARD M. MD

    • Director
    		 71,229 2017-08-03 0

    STEHMAN-BREEN CATHERINE SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-04-03 0

    KRESS JEAN-PAUL

    • Director
    		 2,000 2017-03-10 0

    WOOD JOAN VP, HUMAN RESOURCES

    • Officer
    		 14,926 2016-09-20 0

    APHALE JAYANT VP, TECHNICAL OPERATIONS

    • Officer
    		 No longer subject to file 2016-09-19 0

    PRICE BEN GIL

    • Director
    		 42,830 2016-03-14 0

    GOOLSBEE WILLIAM ALDEN

    • Director
    		 8,166 2016-02-29 0

    HODGMAN JOHN

    • Director
    		 6,333 2015-02-27 0

    CHASE ANTHONY R

    • Director
    		 67,194 2015-02-27 0

    CHRISTOPHER NISHAN GARABEDIAN PRESIDENT AND CEO

    • Officer
    • Director
    		 402,552 2015-02-27 0

    KRIEG ARTHUR M SVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2014-01-13 0

    MARTIGNETTI ANTHONY

    • SEE REMARKS
    		 0 2013-06-04 0

    JACOBSEN MICHAEL A VP OF FINANCE AND PAO

    • Officer
    		 7,500 2012-08-23 0

    MILE MELINDA G CONTROLLER AND PAO

    • Officer
    		 0 2011-08-31 0

    TOSHAV BRACHA EPHRAT SR VP & GENERAL COUNSEL

    • Officer
    		 0 2011-08-31 0

    LINSLEY PETER S SVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2011-05-16 0

    BOYLE J DAVID II CEO

    • Officer
    		 70,282 2010-08-27 0

    WELLER DWIGHT D SR. VP CHEMISTRY & MFG.

    • Officer
    		 0 2010-08-23 0

    IVERSEN PATRICK L SR VP OF RESEARCH & DEVLOPMENT

    • Officer
    		 0 2010-08-23 0

    SHREWSBURY STEPHEN B SVP/REGULATORY AFFAIRS

    • Officer
    		 0 2010-08-23 0

    MEDEIROS PAUL SVP BUSINESS DEVELOPMENT

    • Officer
    		 0 2010-08-23 0

    JOHNSON GRAHAM SR VP PRECLINICAL DEV & RSRCH

    • Officer
    		 0 2010-08-23 0

    HUDSON LESLIE FORMER CEO

    • Officer
    • FORMER CEO
    		 384,559 2010-07-30 0

    HAYWOOD GEORGE WEAVER

    HAYWOOD CHERYL

    • MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER
    		 8,329,126 2010-03-16 0

    ROCKALL EMERGING MARKETS MASTER FUND LTD

    O'DRISCOLL CONOR

    EGAN CON

    MELDRUM ASSET MANAGEMENT, LLC

    • MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER
    		 2,935,696 2010-03-16 0

    EASTBOURNE CAPITAL MANAGEMENT LLC/CA

    • 10% Owner
    		 No longer subject to file 2010-03-04 0

    KOLE RYSZARD SVP/DISCOVERY RESEARCH

    • Officer
    		 1,862,926 2010-02-09 0

    HAYWOOD GEORGE WEAVER

    • SEE REMARKS BELOW
    		 No longer subject to file 2009-08-21 0

    BLACK BEAR OFFSHORE MASTER FUND LP

    • 10% Owner
    		 9,914,211 2009-05-31 0

    FORREST K MICHAEL OUTSIDE DIRECTOR

    • Officer
    • Director
    		 15,000 2009-05-19 0

    CASEY MICHAEL D

    • Director
    		 5,000 2009-05-19 0

    HENNEY CHRISTOPHER S

    • Director
    		 0 2009-03-31 0

    FARA JOHN W PHD

    • Director
    • DIRECTOR
    		 500 2008-05-20 0

    OHANLEY PETER D SR. VICE PRESIDENT

    • Officer
    		 0 2008-02-28 0

    WEBBER MARK MILES CFO

    • Officer
    		 15,446 2008-02-02 0

    TIMMINS ALAN P PRESIDENT & COO

    • Officer
    		 71,382 2008-02-02 0

    BOWMAN JACK L

    • Director
    		 78,334 2007-05-22 0

    HICKS JAMES B

    • Director
    		 79,334 2007-05-22 0

    BURGER DENIS R CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,180,000 2007-04-03 0

    HORN JOSEPH B VICE PRESIDENT OF CARDIOLOGY

    • Officer
    		 100,000 2006-03-22 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 22:15:06 UTC 2.051 0.269 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 21:45:05 UTC 2.051 0.269 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 21:15:05 UTC 2.051 0.269 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 20:45:05 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 20:15:05 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 19:45:03 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 19:15:04 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 18:45:04 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 18:15:05 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 17:45:04 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 17:15:04 UTC 2.057 0.263 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 16:45:03 UTC 2.0555 0.2645 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 16:15:03 UTC 2.0555 0.2645 2000000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 15:45:04 UTC 2.0555 0.2645 1800000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 15:15:05 UTC 2.0555 0.2645 1800000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 14:45:03 UTC 2.0555 0.2645 1800000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 14:15:04 UTC 2.0555 0.2645 1800000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 13:45:05 UTC 2.0457 0.2743 1800000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 13:15:04 UTC 2.0457 0.2743 1600000
    SAREPTA THERAPEUTICS INC SRPT 2022-08-08 12:45:05 UTC 2.0457 0.2743 1600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund SRPT -968.0 shares, $-124910.72 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund SRPT -705.0 shares, $-90973.2 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund SRPT -2819.0 shares, $-212327.08 2019-09-30 N-PORT
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund SRPT -22.0 shares, $-3089.46 2020-09-30 N-PORT
    American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund SRPT -9436.0 shares, $-710719.52 2019-09-30 N-PORT
    Jackson Variable Series Trust- JNL/Nicholas Convertible Arbitrage Fund SRPT -9960.0 shares, $-974287.2 2020-03-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund SRPT -47.0 shares, $-4597.54 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund SRPT -33.0 shares, $-3228.06 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund SRPT -87.0 shares, $-8510.34 2020-03-31 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund SRPT -854.0 shares, $-63648.62 2021-03-31 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund SRPT -800.0 shares, $-73984.0 2021-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio SRPT -12700.0 shares, $-1174496.0 2021-09-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund SRPT -2572.0 shares, $-200924.64 2022-03-31 N-PORT
    AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF SRPT -3179.0 shares, $-248343.48 2022-03-31 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund SRPT -174500.0 shares, $-12619840.0 2022-04-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund SRPT -148.0 shares, $-10703.36 2022-04-30 N-PORT
    VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND SRPT -1393.0 shares, $-100741.76 2022-04-30 N-PORT

    Elevate your investments